Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

Angela R. Branche, Department of Medicine, University of Rochester VTEU, Rochester, New York, USA.
Nadine G. Rouphael, Department of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.
Cecilia Losada, Department of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.
Lindsey R. Baden, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Evan J. Anderson, Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, Georgia, USA.
Anne F. Luetkemeyer, Zuckerberg San Francisco General, University of California San Francisco, San Francisco, California, USA.
David J. Diemert, George Washington Vaccine Research Unit, George Washington University, Washington DC, USA.
Patricia L. Winokur, Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA.
Rachel M. Presti, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Angelica C. Kottkamp, Department of Medicine, New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) Manhattan Research Clinic at NYU Grossman School of Medicine, New York, New York, USA.
Ann R. Falsey, Department of Medicine, University of Rochester VTEU, Rochester, New York, USA.
Sharon E. Frey, Saint Louis University, Center for Vaccine Development, St. Louis, Missouri, USA.
Richard Rupp, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
Martín Bäcker, Department of Medicine, NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, New York, USA.
Richard M. Novak, Department of Medicine, University of Illinois at Chicago-Project WISH, Chicago, Illinois, USA.
Emmanuel B. Walter, Department of Pediatrics, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Lisa A. Jackson, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Susan J. Little, Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
Lilly C. Immergluck, Department of Microbiology/Biochemistry/Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
Siham M. Mahgoub, Department of Medicine, Howard University College of Medicine, Howard University Hospital, Washington DC, USA.
Jennifer A. Whitaker, Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
Tara M. Babu, Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Paul A. Goepfert, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Dahlene N. Fusco, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Robert L. Atmar, Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
Christine M. Posavad, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Antonia Netzl, Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
Derek J. Smith, Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
Kalyani Telu, The Emmes Company, LLC, Rockville, Maryland, USA.
Jinjian Mu, The Emmes Company, LLC, Rockville, Maryland, USA.
Mat Makowski, The Emmes Company, LLC, Rockville, Maryland, USA.
Mamodikoe K. Makhene, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Document Type

Journal Article

Publication Date

8-22-2023

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Volume

77

Issue

4

DOI

10.1093/cid/ciad209

Keywords

SARS-CoV-2; vaccine; variant

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Department

Medicine

Link to Full Text

Share

COinS